Public beta© 2026 Adaptrex, LLC
Public beta© 2026 Adaptrex, LLC
Federal grant · project grant (b)
Developing Blood-based Exercise Mimetic as a Treatment for Alzheimer's Disease and Related Dementias - Project Summary Despite the Growing Number of Adults That Are Living With Alzheimer’s Disease (AD) Worldwide, There Still Lacks Disease Modifying Treatments. Physical Activity and Exercise Mitigate Ad Risk and Boosts Cognitive Functions in Patients, Yet Over a Quarter of the Elderly Do Not Meet These Activity Guidelines, Often Due to Physical Limitations and Resource Constraints. Current Therapeutic Approaches Focused on Ad Are Restricted to Targeting Neuropathology Within the Central Nervous System. Thus, There Is an Imperative Need to Develop Alternative Therapies That Confer Benefits of Exercise to Ad Patients, Circumventing Their Physical Limitations. Prior Work by Our Research Team Identified Glycosylphosphatidylinositol-specific Phospholipase D1 (GPLD1) an Exercise-induced Circulating Factor in Blood Plasma That Mediates the Neurogenic and Cognitive Benefits of Exercise in Aged Mice and Shows Neurobehavioral Relevance in Elderly Human Adults. Systemically Increasing GPLD1 Levels in Blood Mimicked the Beneficial Effects of Exercise on Cognitive Function and Ad-related Neuropathology in Aged Mice and Mouse Models of Ad Pathology. the Purpose of This Study Is to Translate the Scientific Discoveries Identifying Peripheral Targets in Blood – GPLD1 in Particular – as Novel Potential Therapeutic Blood-based Exercise Mimetics to Treat Ad- Related Dementias. We Will Achieve This With Three Specific Aims: 1: Identify Three Lead Recombinant Human GPLD1 Molecules. 2: Establish Optimal Exposure Through Extensive in Vivo PK Profiling in Aged Wild Type Mice of the Three Lead Recombinant Human GPLD1 Molecules. 3: Test One Primary and One Alternate Lead Recombinant Human GPLD1 Molecule for Disease Modification in the 5XFAD Mouse Model of Ad Pathology. Successful Completion of These Aims Is the Critical First Step for the Identification and Commercialization of Potential Therapeutic Blood- Based Exercise Mimetics to Treat Ad-related Dementias.
Committed
$509,038
Paid out
$414.1K
81%
Committed, not yet paid
$95.0K
19%
Loading…
Everything here is this single award's whole record — signed, amended, paid — not a fiscal-year slice. The by-year charts elsewhere split an award across the years it was committed; this page keeps it whole.
Committed is what the government has legally promised on this award so far. Contracts can also carry a ceiling — the maximum if every option is exercised. Unspent ceiling is headroom, not money owed.
The cash actually disbursed against this award. The gap from committed is the disbursement pipeline: promised, not yet cashed.
Each transaction is a signing event — an action that created or changed the award, dated the day it was signed — not a payment. Negative amounts are real: money de-committed at closeout or renegotiation.
One bar, the award’s whole arithmetic: paid out, then committed, not yet paid, then unspent ceiling.